BioMarin Pharmaceutical Inc. (BMRN)

Market Cap	12.51B
Revenue (ttm)	2.75B
Net Income (ttm)	322.29M
Shares Out	190.58M
EPS (ttm)	1.68
PE Ratio	39.07
Forward PE	18.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,641,771
Open	64.90
Previous Close	65.00
Day's Range	64.07 - 66.27
52-Week Range	61.15 - 99.25
Beta	0.29
Analysts	Buy
Price Target	94.20 (+43.47%)
Earnings Date	Oct 29, 2024

About BMRN

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inher...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 23, 1999
• Employees: 3,401
• Stock Exchange: NASDAQ
• Ticker Symbol: BMRN
• Website: https://www.biomarin.com

Financial Performance

In 2023, BioMarin Pharmaceutical's revenue was $2.42 billion, an increase of 15.42% compared to the previous year's $2.10 billion. Earnings were $167.65 million, an increase of 18.43%.

Analyst Forecast

According to 21 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is $94.2, which is an increase of 43.47% from the latest price.

Price Target

$94.2

(43.47% upside)

Analyst Consensus: Buy